2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
January 22nd, 2025
Version: 1
University of Texas Health San Antonio
cancer biology
biorxiv

Tobacco smoke carcinogens exacerbate APOBEC mutagenesis and carcinogenesis

Durfee, C.Open in Google Scholar•Bergstrom, E. N.Open in Google Scholar•Diaz-Gay, M.Open in Google Scholar•Zhou, Y.Open in Google Scholar•Temiz, N. A.Open in Google Scholar•Ibrahim, M. A.Open in Google Scholar•Nandi, S. P.Open in Google Scholar•Wang, Y.Open in Google Scholar•Liu, X.Open in Google Scholar•Steele, C. D.Open in Google Scholaret al.

Mutations in somatic cells are inflicted by both extrinsic and intrinsic sources and contribute over time to cancer. Tobacco smoke contains chemical carcinogens that have been causatively implicated with cancers of the lung and head & neck. APOBEC family DNA cytosine deaminases have emerged as endogenous sources of mutation in cancer, with hallmark mutational signatures (SBS2/SBS13) that often co-occur in tumors of tobacco smokers with an equally diagnostic mutational signature (SBS4). Here we challenge the dogma that mutational processes are thought to occur independently and with additive impact by showing that 4-nitroquinoline 1-oxide (NQO), a model carcinogen for tobacco exposure, sensitizes cells to APOBEC3B (A3B) mutagenesis and leads to synergistic increases in both SBS2 mutation loads and oral carcinomas in vivo. NQO-exposed/A3B-expressing animals exhibit twice as many head & neck lesions as carcinogen-exposed wildtype animals. This increase in carcinogenesis is accompanied by a synergistic increase in mutations from APOBEC signature SBS2, but not from NQO signature SBS4. Interestingly, a large proportion of A3B-catalyzed SBS2 mutations occurs as strand-coordinated pairs within 32 nucleotides of each other in transcribed regions, suggesting a mechanism in which removal of NQO-DNA adducts by nucleotide excision repair exposes short single-stranded DNA tracts to enzymatic deamination. These highly enriched pairs of APOBEC signature mutations are termed didyma (Greek for twins) and are mechanistically distinct from other types of clustered mutation (omikli and kataegis). Computational analyses of lung and head & neck tumor genomes show that both APOBEC mutagenesis and didyma are elevated in cancers from smokers compared to non-smokers. APOBEC signature mutations and didyma are also elevated in normal lung tissues in smokers prior to cancer initiation. Collectively, these results indicate that DNA adducting mutagens in tobacco smoke can amplify DNA damage and mutagenesis by endogenous APOBEC enzymes and, more broadly, suggest that mutational mechanisms can interact synergistically in both cancer initiation and promotion.

Similar Papers

biorxiv
Thu May 08 2025
Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes
As cancer cell specific rewiring of metabolic networks creates potential therapeutic opportunities, we conducted a synthetic lethal screen utilizing inhibitors of metabolic pathways. Simultaneous administration of (R)-GNE-140 and BMS-986205 (Linrodostat) preferentially halted proliferation of ovarian cancer cells, but not of their non-oncogenically transformed progenitor cells. While (R)-GNE-140 i...
Dreute, J.
•
Stengel, J.
•
Becher, J.
•
van den Borre, D. R.
...•
Schmitz, M. L.
biorxiv
Thu May 08 2025
Loss of ATG5 expression in a subset of human prostate cancers promotes tumor growth through accumulation of p62
Loss-of-function mutations in autophagy-related (ATG) genes are rare in cancer. However, we report herein that ATG5 is fully deleted in ~14% of prostate cancers (PCa), rivaling that of well-established tumor suppressor genes. ATG5 expression was downregulated at both mRNA and protein levels and was associated with poor patient survival. The DU145 PCa cell line, isolated from a brain metastasis, is...
Wible, D. J.
•
Li, W.
•
Liu, X.
•
Sebastian, M. M.
...•
Bratton, S. B.
biorxiv
Thu May 08 2025
WITHDRAWN: Oncostratifier: Stratifying Oncogene-addicted Cohorts By Drug Response
Oncogenes, when mutated or overexpressed, drive tumorigenesis and can lead to oncogene addiction, where cancer cells rely on such genes for survival and proliferation. Stratifying oncogene-addicted cohorts is essential to uncover alternative therapeutic avenues, for instance in cases of untargetable oncogenes or resistance to treatment. We propose Oncostratifier, a framework to identify drugs that...
Tepeli, Y. I.
•
Trastulla, L.
•
Goncalves, J. P.
•
Iorio, F.
biorxiv
Thu May 08 2025
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewal.
DNA hypomethylating agents (HMAs) are used to treat acute myeloid leukemia (AML) and myelodysplasia patients who are unsuitable for intensive chemotherapy. However, low response rates and therapy-resistant relapse remain significant challenges. To improve outcomes, we must understand how AML cells survive HMA treatment and continue to proliferate following therapy. We combine single-cell multiomic...
Bond, D. R.
•
Burnard, S. M.
•
Uddipto, K.
•
Hunt, K. V.
...•
Lee, H. J.
biorxiv
Thu May 08 2025
Metabolic modulation of intratumoral cholesterol with gut microbiota for the treatment of colorectal cancer
Excess cholesterol is positively correlated with colorectal cancer (CRC). Current therapeutic strategies for modulating cholesterol levels in CRC are limited and often come with complications. Here, we demonstrated that microbiome shunting of intestinal cholesterol to anticancer metabolites is a safe and applicable therapeutic approach for CRC. By screening major microbial metabolic products of ch...
Wu, J.
•
Lai, Y.
•
Li, J.
•
Zhai, L.
...•
Wong, H. L. X.
biorxiv
Thu May 08 2025
Plasma Exosomes in Insulin Resistant Obesity Exacerbate Progression of Triple Negative Breast Cancer
Breast cancer, the most common cancer among women worldwide, continues to pose significant public health challenges. Among the subtypes of breast cancer, triple-negative breast cancer (TNBC) is particularly aggressive and difficult to treat due to the absence of receptors for estrogen, progesterone, or human epidermal growth factor receptor 2, rendering TNBC refractory to conventional targeted the...
Llevenes, P.
•
Chen, A.
•
Lawton, M. L.
•
Rondon-Ortiz, A. N.
...•
Denis, G. V.
biorxiv
Wed May 07 2025
Miro1 knockout inhibits mouse breast cancer tumorigenesis
Miro1 is a mitochondrial outer membrane protein that regulates mitochondrial and peroxisome trafficking, endoplasmic reticulum (ER) association, and mitophagy. Prior studies suggest a role for Miro1 in cell migration and proliferation in both normal and tumor cells. High Miro1 expression is associated with poor overall survival in breast cancer patients. To investigate the role of Miro1 in breast ...
Termos, R.
•
Muskat, A.
•
Shannon, N.
•
McCoy, M.
...•
Cunniff, B.
biorxiv
Wed May 07 2025
IRE1α and IRE1β Protect Intestinal Epithelium and Suppress Colorectal Tumorigenesis through Distinct Mechanisms
Intestinal epithelial cells (IECs) uniquely express two IRE1 paralogues, IRE1 and IRE1{beta}, whose roles in intestinal physiology are incompletely understood. We examined the individual and cooperative functions of IRE1 and IRE1{beta} in IECs using mice using intestine-specific deletion of Ire1 or germline Ire1{beta} deletion, and subsequently with double deleted Ire1, Ire1{beta} mice. At baselin...
Deng, R.
•
Wang, M.
•
Promlek, T.
•
Druelle-Cedano, C.
...•
Kaufman, R. J.
biorxiv
Wed May 07 2025
Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic regulators of glioma growth
Diffuse infiltrating gliomas are aggressive tumors of the central nervous system driven by intra-tumoral heterogeneity and aberrant normal-tumor cell-cell interactions. Grade specific and locoregional metabolic dependencies driving aberrant cell-states linked to treatment resistance, seizures and infiltration of gliomas remain elusive. Here, we applied spatial transcriptomics (stRNAseq), imaging m...
Ma, Y.
•
Ayadhury, S.
•
Singh, S.
•
Vashishath, Y.
...•
Ene, C. I.
biorxiv
Wed May 07 2025
Insights into gallbladder cancer pathogenesis from a living organoid gallbladder cholangiocyte biorepository
Gallbladder cancer (GBC) while rare worldwide has a high prevalence in India. Pathogenesis is unclear and outcomes poor. Gallbladder cholangiocyte organoids (GCOs) or gallbladder carcinoma organoids (GBCOs) were developed and serially propagated from surgically resected gallbladder tissues with benign or malignant diseases, respectively. Patient derived organoids (PDOs) were derived from 15 normal...
Dutta, A.
•
Chowdhury, N.
•
Selvarajan, A. V.
•
Banerjee, P.
...•
GuhaSarkar, D.